Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

KNSA XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

4.8B

Short interest (Jul 15)

5.9%

Net Short (Jul 27 ): 0.0%

Borrow Fee

0.41%

↓ 1.6%

Available Shares

400K

↓ 36.3%

Price Chart

Company Overview

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001730430

Asset Type: CS

Market Data

Market Cap: $4,834,784,925

Employees: 366

Status: Active

Short Interest

Current Borrow Fee 0.41%

Range: 0.41% - 0.41%

Available Shares 400K

Range: 300K - 400K

Recent Changes

Fee Change: ↓ 0.0%

Available Change: ↓ 0.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime